BL 1832
Latest Information Update: 01 Mar 2007
At a glance
- Originator Bioglan Pharma [CEASED]; Winston Laboratories
- Developer Bioglan Pharma [CEASED]
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 31 Dec 2002 Discontinued - Phase-III for Pain (Topical)
- 18 Jun 2001 Phase-III clinical trials for Pain (Topical)